Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults

A legfontosabb adatok

Ki végzi
AstraZeneca
Hol
Beijing és Hubei (Kína)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
10 fő, tervezett
Kezdés
2026. aug. 18.
Várható befejezés
2027. aug. 31.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Observational, None intervention
A regiszteradat frissítve
2026. október 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults in China with dilated cardiomyopathy (an enlarged, weak heart muscle) linked to a BAG3 gene change. It only observes and records how the disease develops.

Életkor
18 years or older
Nem
Male or female
A betegség stádiuma
Heart failure Stage B or C, NYHA class I-III. LVEF (heart pumping strength) of 50% or less, measured by heart ultrasound or heart MRI within the past 12 months.
Korábbi kezelés
People who have had gene or cell therapy cannot join. No investigational drug in the 30 days before screening.
Biomarker vagy leletérték
A BAG3 pathogenic or likely pathogenic mutation, judged by ACMG guidelines. If LVEF is 45%-50% with Stage B or NYHA class I, NT-proBNP must be 300 pg/mL or higher.

A részvétel fő kizáró okai

  • Sudden worsening of heart failure in the past 1 month
  • Heart attack, heart surgery, ICD implant, acute coronary syndrome or hospital stay for heart rhythm problems in the past 3 months
  • Past heart transplant, or expected need for a heart transplant, heart pump or heart surgery in the next 3 months
  • eGFR below 30 mL/min/1.73 m² (poor kidney function)
  • Active cancer or cancer found in the past 3 years, with some exceptions

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must meet all of the following criteria to be eligible for inclusion:; Age ≥18 years at screening, male or female; Presence of a BAG3 pathogenic or likely pathogenic mutation interpreted according to the American College of Medical Genetics and Genomics (ACMG) guidelines; Heart failure (HF) Stage B or C, New York Heart Association (NYHA) functional class I-III; LVEF ≤50%. If LVEF is 45%-50% and the participant is classified as Stage B heart failure or NYHA Class I, N-terminal pro-B-type natriuretic peptide (NT-proBNP) must be ≥300 pg/mL. LVEF measurement must be based on echocardiography or cardiac magnetic resonance results within the past 12 months; Willing and able to comply with all scheduled visits, laboratory tests, and other study procedures; Capable of providing signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form and this protocol

Ki nem vehet részt

  • Participants meeting any of the following criteria will be excluded:; Acute decompensated heart failure within 1 month prior to enrollment; Any of the following within 3 months prior to screening:; Myocardial infarction; Cardiac surgical procedures (excluding pacemaker/implantable cardioverter defibrillator/cardiac resynchronization therapy implantation); Implantable cardioverter defibrillator (ICD) implantation; Acute coronary syndrome; Hospitalization for cardiac arrhythmia; History of heart transplantation; Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula); Active malignancy or malignancy diagnosed within 3 years prior to screening, except for:; Surgically cured in situ malignancies; Surgically cured early-stage cancers (including breast, prostate, skin [basal cell carcinoma, squamous cell carcinoma], thyroid, or cervical cancer); Other early-stage malignancies with an expected 2-year recurrence rate ≤20%, approved by the Medical Monitor; Non-cardiac condition limiting life expectancy to <1 year; Presence of any of the following cardiac conditions:; Other forms of cardiomyopathy contributing to heart failure (e.g., inflammatory or infiltrative cardiomyopathy); Clinically significant cardiac anatomic abnormalities (e.g., left ventricular aneurysm); Significant coronary artery disease (e.g., prior revascularization, exercise-induced angina); Uncorrected, hemodynamically significant (moderate to severe) primary structural valvular disease not due to heart failure (investigator's judgment); Any severe concurrent disease (e.g., active systemic infection) that, in the investigator's judgment, would make the participant unsuitable for study participation; Any medical or psychiatric condition that may increase study risk, including:; Active or recent (within 1 year) suicidal ideation/behavior; Laboratory abnormalities; Other conditions deemed unsuitable by the investigator; Administration of any investigational drug within 30 days prior to screening; Prior gene or cell therapy treatment; Anticipated need for cardiac transplantation, left ventricular assist device implantation, or other cardiac surgery within the next 3 months (investigator's assessment); More than 3 first-degree relatives from the same family enrolled concurrently (excluding the participant)

Helyszínek itt: Kína

  • BeijingHospital not named in the registryContact: Zhuang Tian, DoctoralRésztvevőt keres
  • HubeiHospital not named in the registryToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicentre, prospective cohort study designed to elucidate the natural history of dilated cardiomyopathy (DCM) associated with specific gene mutations in Chinese patients. By establishing a cohort of patients with inherited cardiomyopathy, the study will collect comprehensive data, including demographic characteristics, disease history, clinical features, prior treatments, current treatment patterns, clinical outcomes, and patient-reported outcomes (PROs). The objective is to describe the disease profile, current diagnostic and therapeutic landscape, clinical progression, and prognosis of this specific patient population in China. The data generated will provide a foundational basis for deepening the understanding of disease progression, identifying unmet clinical needs, and exploring potential surrogate endpoints for future clinical trials in drug development. The study plans to enroll 10 eligible patients with BCL-2-associated athanogene 3 (BAG3)-associated inherited DCM from 3 research sites across China.

A vizsgálat csoportja

  • patients with BAG3 DCM

    Approximately 10 patients with BAG3 DCM will be enrolled from 3 research sites in China. Comprehensive clinical data, including demographic characteristics, medical history, clinical manifestations, treatment records, clinical outcomes, and PROs, will be collected.

    Kezelés: Observational, None intervention

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults: A Multicentre, Prospective, Observational Cohort Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. október 22.